Skip Navigation

Cardiovascular Research 2003 58(2):313-323; doi:10.1016/S0008-6363(03)00264-5
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nir, S. G.
Right arrow Articles by Itskovitz-Eldor, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nir, S. G.
Right arrow Articles by Itskovitz-Eldor, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Human embryonic stem cells for cardiovascular repair

Sharon Gerecht Nira,b, Robert Davidc, Marc Zarubac, Wolfgang-M. Franzc and Joseph Itskovitz-Eldorb,d,*

aBiotechnology Interdisciplinary Unit, Technion—Israel Institute of Technology, Haifa, Israel
bDepartment of Obstetrics and Gynecology, Rambam Medical Center, P.O. Box 9602, Haifa 31096, Israel
cMedical Department I, Ludwig-Maximilians University, Klinikum Grosshadern, Munich, Germany
dFaculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel

itskovitz{at}rambam.health.gov.il

* Corresponding author. Tel.: +972-4-854-2536; fax: +972-4-854-2503.

The critical loss of functional cardiomyocytes causes severe deterioration of pump function, resulting in heart failure. The possibility to regenerate or repair damaged or ischemic cardiac tissue is a great challenge for the future treatment of end-stage heart failure. As cardiomyocytes cannot be regenerated in adults, current therapeutic modalities for the treatment of end-stage heart failure are limited and include medical therapy, mechanical left ventricular assist devices, and cardiac transplantation. This review will focus on the potential use of human embryonic stem (hES) cell-derived cardiomyocytes and vascular cells, as a therapeutic tool for the treatment of myocardial infarction and end-stage heart failure.

KEYWORDS Ischemia; Stem cells; Developmental biology; Myocytes; Angiogenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.